Ms. Samira Sakhia reports

KNIGHT THERAPEUTICS ANNOUNCES REPAYMENT OF REVOLVING CREDIT FACILITY

Knight Therapeutics Inc. has repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders.

The credit facility provides borrowing capacity of up to $100-million (U.S.), with an additional $100-million (U.S.) accordion feature subject to certain conditions. In June, 2025, Knight drew $60-million from the credit facility to support the acquisition of Paladin. The company has repaid all outstanding amounts under the credit facility.

"Today marks the one-year anniversary of the Paladin transaction, and we are proud that we have repaid within a year the credit we withdrew to finance the acquisition," said Arvind Utchanah, chief financial officer of Knight. "The repayment which was made within a year was funded by the strong cash flow generated by our business in Canada and Latin America. We appreciate the ongoing support of our financing partners, and, with our revolving credit facility providing capacity of up to $200-million (U.S.), we remain well positioned to execute our long-term growth strategy."

About Knight Therapeutics Inc.

Knight, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.